Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors

被引：2

作者：

Lin, C-C. ^{[1
]}

Grewal, J. ^{[2
]}

Baranda, J. C. ^{[3
]}

Schneider, R. E. ^{[4
]}

Zhang, J. ^{[5
]}

Bai, L-Y. ^{[6
]}

Yeh, Y-M. ^{[7
]}

Sommerhalder, D. ^{[8
]}

Li, G. ^{[9
]}

Shen, L. ^{[10
]}

Hsu, H-C. ^{[11
]}

Alese, O. ^{[12
]}

Yin, R. ^{[13
]}

Hsieh, C-Y. ^{[14
]}

Cai, S. X. ^{[15
]}

Tian, Y. E. ^{[16
]}

Xia, H. ^{[14
]}

Li, B. ^{[14
]}

Zhang, M. ^{[14
]}

Zhang, C. ^{[14
]}

机构：

[1] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[2] Norton Canc Inst, Med Oncol, Louisville, KY USA

[3] Univ Kansas, Clin Res Ctr, Med Oncol Dept, Kansas City, KS USA

[4] Mary Crowley Canc Res Ctr, Outpatient Evaluat & Treatment Ctr Texas Oncol, Dallas, TX USA

[5] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Shanghai, Peoples R China

[6] China Med Univ Hosp, Div Hematol & Oncol, New Taipei, Taiwan

[7] NCKUH Natl Cheng Kung Univ Hosp, Oncol, Tainan, Taiwan

[8] NEXT Oncol, Oncol, San Antonio, TX USA

[9] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Gynaecol Oncol, Wuhan, Peoples R China

[10] Beijing Canc Hosp, Dept Digest Oncol, Beijing, Peoples R China

[11] Linkou Chang Gung Mem Hosp, Chang Gung Med Fdn, Oncol, Taoyuan, Taiwan

[12] Emory Univ Hosp, Hematol & Med Oncol, 1364 Clifton Rd NE, Atlanta, GA 30322 USA

[13] Sichuan Univ, West China Womens & Childrens Hosp, West China Univ Hosp 2, Dept Oncol & Chemoradiotherapy, Chengdu, Peoples R China

[14] IMPACT Therapeut Inc Shanghai, Clin Dev, Shanghai, Peoples R China

[15] IMPACT Therapeut Inc Shanghai, Dev, Shanghai, Peoples R China

[16] IMPACT Therapeut Inc Shanghai, Res, Shanghai, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1848

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

662MO

引用

页码：S466 / S466

页数：1

共 50 条

[1] A phase 1 dose-escalation and -expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors.
Lin, Chia-Chi
Grewal, Jaspreet Singh
Sommerhalder, David
Strauss, James Fredric
Bai, Li-Yuan
Shen, Lin
Yeh, Yu-Min
Hsieh, Chih-Yi
Cai, Sui Xiong
Tian, Ye Edward
Xia, Huan
Zhang, Congcong
Li, Baoyue
Zhang, Ming
Ma, Ning
Zhao, Liping
Ma, Jie
Shi, Huiyan
Yu, Zhixin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] Safety, pharmacokinetic (PK), and pharmacodynamic profiles of the WEE1 inhibitor IMP7068 in patients (pts) with advanced solid tumors
Lin, C-C.
Grewal, J.
Sommerhalder, D.
Bai, L-Y.
Li, G.
Schneider, R.
Shen, L.
Yeh, Y-M.
Yin, R.
Hsu, H-C.
Baranda, J. C.
Hsieh, C-Y.
Cai, S. X.
Tian, Y. E.
Ma, N.
Xia, H.
Zhang, C.
Li, B.
Zhang, M.
Yu, Z.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S760 - S761
[3] A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors
Ferrarotto, R.
Eckhardt, G.
Patnaik, A.
LoRusso, P.
Faoro, L.
Heymach, J. V.
Kapoun, A. M.
Xu, L.
Munster, P.
ANNALS OF ONCOLOGY, 2018, 29 (07) : 1561 - 1568
[4] A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors
Patnaik, Amita
Hamilton, Erika
Xing, Yan
Rasco, Drew W.
Smith, Lon
Lee, Ya-Li
Fang, Steven
Wei, Jiao
Hui, Ai-Min
CANCERS, 2022, 14 (20)
[5] A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
Harding, James J.
Telli, Melinda
Munster, Pamela
Voss, Martin H.
Infante, Jeffrey R.
DeMichele, Angela
Dunphy, Mark
Le, Mai H.
Molineaux, Chris
Orford, Keith
Parlati, Frank
Whiting, Sam H.
Bennett, Mark K.
Tannir, Nizar M.
Meric-Bernstam, Funda
CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4994 - 5003
[6] CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, openlabel, dose-escalation and dose expansion study
Li, K.
Wu, J.
Ye, S.
Liu, Y.
Huang, H.
Fan, F.
Lai, Y.
Zhuang, S.
Zhou, L.
Huang, R.
Teng, Y.
Chai, X.
Zhang, J.
Shi, Y.
Huang, H.
ANNALS OF ONCOLOGY, 2023, 34 : S991 - S991
[7] First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors
Li, Wei
Wang, Yongsheng
Xiong, Anwen
Gao, Ge
Song, Zhengbo
Zhang, Yiping
Huang, Dingzhi
Ye, Feng
Wang, Qiming
Li, Zhihui
Liu, Jiaye
Xu, Chunwei
Sun, Yinghui
Liu, Xijie
Zhou, Fei
Zhou, Caicun
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
[8] A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors.
Li, Kaiwen
Wu, Junyan
Ye, Suiwen
Liu, Yanqiong
Huang, Hao
Fan, Fan
Lai, Yiming
Zhuang, Suili
Zhou, Liyan
Huang, Robert
Xu, Mo
Pan, Bin
Zhang, Jian
Shi, Yehui
Huang, Hai
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors.
Sonpavde, Guru P.
Call, Justin A.
Falchook, Gerald Steven
Garmezy, Benjamin
Rasco, Drew W.
Liu, Lan
Niu, Tiantian
He, Jenna
Zhang, Congcong
Kochan, Jarema
Rebello, Sam
Russo, Giuseppe
Chen, Viola
Krishnan, Suba
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[10] Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
Li, Huiping
Liu, Rongrui
Shao, Bin
Ran, Ran
Song, Guohong
Wang, Ke
Shi, Yehui
Liu, Jihong
Hu, Wenjing
Chen, Fu
Liu, Xiaoran
Zhang, Gairong
Zhao, Chuanhua
Jia, Ru
Wang, Quanren
Rugo, Hope S.
Zhang, Yifan
Li, Guangze
Xu, Jianming
CHINESE JOURNAL OF CANCER RESEARCH, 2020, 32 (03) : 370 - +

← 1 2 3 4 5 →